Fusion of an albumin-binding domain extends the half-life of immunotoxins
Guo R, et al.
International Journal of Pharmaceutics, 511(1), 538-549 (2016)
Alexander Weng et al.
Molecular oncology, 6(3), 323-332 (2012-02-09)
Tumor-targeting protein toxins are composed of a toxic enzyme coupled to a specific cell binding domain that targets cancer-associated antigens. The anti-tumor treatment by targeted toxins is accompanied by dose-limiting side effects. The future prospects of targeted toxins for therapeutic...
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.
Bewarder, et al.
Cancer Immunology, Immunotherapy, 69, 1535-1548 (2020)
Alexander N Wein et al.
Journal of medicinal chemistry, 55(18), 7998-8006 (2012-09-08)
Protective antigen (PA), lethal factor, and edema factor, the protein toxins of Bacillus anthracis , are among its most important virulence factors and play a key role in infection. We performed a virtual ligand screen of a library of 10000...
Yi Hu et al.
Leukemia research, 35(9), 1254-1260 (2011-02-08)
We have previously demonstrated that CCR9 plays a pivotal role in drug resistance and invasion in human acute T-lymphocytic leukemia (T-ALL). In this study, we investigated whether the MOLT4 cells, which naturally express CCR9 at high levels, can be successfully...